- Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
- Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Arcutis Appoints David Topper as Chief Financial Officer
- Arcutis Promotes Todd Tucker to Chief Human Resources Officer
- Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
- New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
- Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
- Arcutis Announces Pricing of $150 Million Public Offering
More ▼
Key statistics
On Tuesday, Arcutis Biotherapeutics Inc (ARQT:NSQ) closed at 8.88, -32.57% below its 52-week high of 13.17, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.33 |
---|---|
High | 9.54 |
Low | 8.85 |
Bid | 8.71 |
Offer | 8.90 |
Previous close | 8.88 |
Average volume | 4.18m |
---|---|
Shares outstanding | 115.76m |
Free float | 113.26m |
P/E (TTM) | -- |
Market cap | 1.03bn USD |
EPS (TTM) | -2.91 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼